PO

Polaris AI Pharma Corp.

A global supplier of generic APIs using AI to accelerate drug development.

041910 | KO

Overview

Corporate Details

ISIN(s):
KR7041910001
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 발안공단로 25, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Polaris AI Pharma Corp., formerly Estechpharma, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs). The company specializes in the production of generic APIs, with a portfolio of approximately 40 products for various therapeutic areas, including anti-thrombotic, anti-inflammatory, and treatments for gastric ulcers and asthma. A key strategic focus is the integration of artificial intelligence into its research and development pipeline to predict the success of drug candidates and optimize clinical trial designs, thereby accelerating the development process. Polaris AI Pharma serves both domestic and international pharmaceutical markets and engages in joint research for innovative drug delivery systems.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 884.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-12 00:00
M&A Activity
[기재정정]주요사항보고서(유형자산양수결정)
Korean 19.8 KB
2025-08-12 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 15.7 KB
2025-08-07 00:00
M&A Activity
[기재정정]주요사항보고서(유형자산양수결정)
Korean 20.0 KB
2025-08-01 00:00
Capital/Financing Update
단기차입금증가결정
Korean 9.5 KB
2025-07-07 00:00
M&A Activity
주요사항보고서(유형자산양수결정)
Korean 15.9 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 907.9 KB
2025-03-20 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.5 KB
2025-03-12 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 540.9 KB
2025-03-12 00:00
Audit Report / Information
감사보고서제출
Korean 19.4 KB
2025-03-05 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.4 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.9 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 118.6 KB
2024-12-16 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB

Automate Your Workflow. Get a real-time feed of all Polaris AI Pharma Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Polaris AI Pharma Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Polaris AI Pharma Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
AGENUS INC Logo
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.